Dr. Fowke is currently considering graduate student applications (updated September 2019)
The Laboratory of Viral Immunology is a vital, active laboratory focused on training scientists at the M.Sc., Ph.D., or postdoctoral levels through basic studies in the immunobiology of HIV infection. The Viral Immunology Laboratory is currently focusing on three major areas of research:
Dr. Fowke has a particular interest in training young investigators and has been involved in a number of workshops and international training programs including the International Infectious Disease and Global Health Training Program (IID&GHTP) and Canadian Queen Elizabeth II Diamond Jubilee Scholarships (QES) Program. Dr. Fowke is also an active member of the Canadian HIV Cure Enterprise (CanCURE), a research collaboration focused on studying HIV persistence and developing strategies towards a functional HIV Cure.
IN THE NEWS
Selected current grants:
1. April 2019-March 2024. Nominated Principal Investigator. Other PIs - Emmanuel Ho, Joshua Kimani, Lyle McKinnon, Thomas Murooka. Co-Is Julie Lajoie, Julius Oyugi. Combination HIV Prevention: Using anti-retroviral and anti-inflammatory medications to prevent new HIV infections. Canadian Institutes for Health Research (CIHR). Team Grant: HIV/AIDS Biomedical and Clinical Research – HIV Prevention – Focused Team. $2,000,000.
5. April 2018-March 2023. Principal Investigator. Co-investigators Joshua Kimani and Julie Lajoie. Reducing HIV target cells in the female genital tract: Determining the mechanism of inducing immune quiescence. Canadian Institutes for Health Research (CIHR), Open Operating Project Grant. $772,650.
6. April 2018-March 2021. PI Keith Fowke; co-investigators Natalie Riediger, Andrew Hatala, Jose Lavoie, Javier Mignone. Promoting International Community-University Partnerships in Global and Indigenous Health. Universities Canada, Queen Elizabeth Scholarships, $300,000.
7. April 2017-March 2020. Nominated PI – Gary Kobinger U Laval. Co-applicant – Keith Fowke. Development of a safe, effective and clinically acceptable VSV-based HIV vaccine. CIHR-IAVI Research Partnership – Optimizing the VSV Vector towards an HIV Vaccine Program. $3.2M. The Fowke Lab receives $60,000/year from this grant.
8. April 2017-March 2022. Nominated PI – Josée Lavoie. Co-applicant – Keith Fowke. The Prairie Indigenous Knowledge Exchange Network (PIKE-Net). CIHR. Indigenous Mentorship Network Program. $1,000,000.
Selected Recent Fowke Lab Journal Articles: (Fowke Lab trainees/staff)
For an up to date link to publications from the Fowke Lab please click here
1. Lajoie J*, Tjernlund A*, Omollo K, Edfeldt G, Röhl M, Boily-Larouche G, Cheruiyot J, Kimani M, Kimani J, Oyugi J, *Broliden K and FOWKE KR*. Increased cervical CD4+CCR5+T cells among Kenyan sex working women using depot medroxyprogesterone acetate. AIDS Res Hum Retroviruses. 2019 Mar;35(3):236-246. doi: 10.1089/AID.2018.0188. Online ahead of editing Dec 26, 2018, Epub Jan 24, 2019 PMID:30585733.
4. *Lajoie J, *Birse K, *Mwangi L, Chen Y, Cheruiyot J, Akolo M, Mungai J, Boily-Larouche G, Romas L, Mutch S, Kimani M, Oyugi J, Ho EA, Burgener A, Kimani J, FOWKE KR. Using safe, affordable and accessible non-steroidal anti-inflammatory drugs to reduce the number of HIV target cells in the blood and at the female genital tract. Journal of the International AIDS Society. (IF 6.3) Jul;21(7):e25150. doi: 10.1002/jia2.25150. PMID: 30047573. * equal contribution.
5. Chen Y, Traore Y, Yang S, Lajoie J, FOWKE KR, Rickey D, Ho EA. Implant delivering hydroxychloroquine attenuates vaginal T lymphocyte activation and inflammation. Journal of Controlled Release. (IF 8.450). May 10;277:102-113. doi: 10.1016/j.jconrel.2018.03.010. Epub 2018 Mar 13.PMID: 29545105
6. Wessels JM, Lajoie J, Vitali D, Omollo K, Kimani J, Oyugi J, Cheruiyot J, Kimani J, Mugai, JN, Akolo M, Stearns JC, Surette MG, FOWKE KR#, Kaushic C#. Association of High-Risk Sexual Behaviour with Diversity of the Vaginal Microbiota and Abundance of Lactobacillus. PLoS One. 2017 Nov 2;12(11):e0187612. doi: 10.1371/journal.pone.0187612. eCollection 2017.PMID: 29095928 #Co-senior authors.
7. Boily-Larouche G, Omollo K, Cheruiyot J, Njoki J, Kimani M, Kimani J, Oyugi J, Lajoie J, and FOWKE KR. CD161 identifies polyfunctional Th1/Th17 cells in the genital mucosa that are depleted in HIV-infected female sex workers from Nairobi, Kenya. Scientific Report. 2017. Sept 11 7: (11123)1-10. DOI:10.1038/s41598-017-11706-y PMID: 28894259
8. Lajoie J, Mwangi L, FOWKE KR. Preventing HIV infection without targeting the virus: how reducing HIV target cells at the genital tract is a new approach to HIV prevention. AIDS Research and Therapy. 2017. 14(46):1-5. DOI 10.1186/s12981-017-0166-7 PMID: 28893304
9. Taborda NA, Hernández JC, Lajoie J, Juno JA, Kimani J, Rugeles MT, FOWKE KR. Low expression of activation and inhibitory molecules on NK cells and CD4+ T-cells is associated with viral control. AIDS Research and Human Retroviruses. 2015. 31(6):636-40. DOI: 10.1089/aid.2014.0325 PMID: 25738606
10. Juno JA, Stalker AT, Waruk J, Oyugi J, Kimani M, Plummer FA, Kimani J, FOWKE KR. Elevated Expression of LAG-3, but not PD-1, is Associated with Impaired iNKT Cytokine Production during Chronic HIV-1 Infection and Treatment. Retrovirology. 2015. 12:1-17 DOI 10.1186/s12977-015-0142-z. PMID: 25810006